Sulfuric Acid

Sulfuric Acid

SCHEMBL637684

COC(=N)N.O=S(=O)([O-])O.[H+]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CYP51cyp51Acyp51c

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
BLM P54132 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40
F2 P00734 4/20 0.38
PRSS1 P07477 4/20 0.38
PRSS2 P07478 4/20 0.38
PRSS3 P35030 4/20 0.38
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA14 Q9ULX7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL5693208 0.95 KDM4E (0.37) KDM4ECYP2D6CYP2C19BLMNPSR1
SCHEMBL8974403 0.87 KDM4E (0.39) KDM4ECYP2D6CYP2C19BLMNPSR1
Sulfuric Acid SCHEMBL601039 0.86 KDM4E (0.52) KDM4ECYP2D6CYP2C19BLMNPSR1
Sulfuric Acid SCHEMBL28052558 0.86 KDM4E (0.52) KDM4ECYP2D6CYP2C19BLMNPSR1
Sulfuric Acid SCHEMBL275165 0.86 KDM4E (0.52) KDM4ECYP2D6CYP2C19BLMNPSR1
Sulfuric Acid SCHEMBL27561650 0.83 KDM4E (0.50) KDM4ECYP2D6CYP2C19BLMNPSR1
SCHEMBL6737394 0.81 KDM4E (0.42) KDM4ECYP2D6CYP2C19BLMNPSR1
Sulfuric Acid SCHEMBL21827141 0.80
SCHEMBL6195802 0.80
SCHEMBL28052556 0.79 KDM4E (0.40) KDM4ECYP2D6CYP2C19BLMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119643873-A Method for efficiently enriching N-terminal modified peptide fragments of various proteins 宁波大学 2025-03-18 CN claimed
CN-113387843-B Method for synthesizing O-methyl isourea hydrogen sulfate 上海凌凯医药科技有限公司 2023-03-24 CN claimed
CN-113387843-A Method for synthesizing O-methyl isourea hydrogen sulfate 上海凌凯医药科技有限公司 2021-09-14 CN claimed
EP-1357952-B1 METHOD FOR COATING MEDICAL DEVICE SURFACES MEDTRONIC INC (US) 2010-09-01 EP claimed
US-20060264608-A1 Bi-directional synthesis of oligoguanidine transport agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-11-23 US claimed
US-20060193968-A1 Method for attachment of biomolecules to medical device surfaces MEDTRONIC, INC. 2006-08-31 US claimed
US-20060099326-A1 Method for attachment of biomolecules to medical device surfaces MEDTRONIC, INC. 2006-05-11 US claimed
US-20040086543-A1 Method for attachment of biomolecules to medical device surfaces MEDTRONIC, INC. 2004-05-06 US claimed
EP-1357952-A2 METHOD FOR COATING MEDICAL DEVICE SURFACES Medtronic, Inc. (US) 2003-11-05 EP claimed
US-6617142-B2 Method for attachment of biomolecules to medical device surfaces MEDTRONIC, INC. 2003-09-09 US claimed
US-20020120333-A1 Method for coating medical device surfaces KEOGH JAMES R (US) 2002-08-29 US claimed
WO-2002060505-A2 METHOD FOR COATING MEDICAL DEVICE SURFACES MEDTRONIC, INC. (US) 2002-08-08 WO claimed
US-20020001834-A1 METHOD FOR ATTACHMENT OF BIOMOLECULES TO MEDICAL DEVICE SURFACES MEDTRONIC, INC. 2002-01-03 US claimed
US-6033719-A Method for covalent attachment of biomolecules to surfaces of medical devices MEDTRONIC, INC. (US) 2000-03-07 US claimed
US-5928916-A Ionic attachment of biomolecules with a guanidino moiety to medical device surfaces MEDTRONIC, INC. (US) 1999-07-27 US claimed
US-5925552-A Method for attachment of biomolecules to medical devices surfaces MEDTRONIC, INC. (US) 1999-07-20 US claimed
EP-0165032-A2 Dihydropyridine anti-ischaemic and antihypertensive agents Pfizer Limited (GB) 1985-12-18 EP claimed
US-3931316-A Method of preparing O-methyl-isourea hydrogen sulfate and O-methyl-isourea sulfate from cyanamide SUDDEUTSCHE KALKSTICKSTOFF-WERKE AG (DT) 1976-01-06 US claimed
US-12517133-B2 Macromolecule analysis employing nucleic acid encoding DF PEPTIDE ACQUISITION LLC 2026-01-06 US disclosed
US-3931316-A Method of preparing O-methyl-isourea hydrogen sulfate and O-methyl-isourea sulfate from cyanamide SUDDEUTSCHE KALKSTICKSTOFF-WERKE AG (DT) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264608-A1 Bi-directional synthesis of oligoguanidine transport agents SLC29A2, SLC1A5, SLC29A1 KDM4E 4428/4885CYP2D6 854/4885CYP2C19 1225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.